pyruvic acid has been researched along with Arteriosclerosis, Coronary in 5 studies
Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed)
pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The results suggested that metabolic products of fatty acid oxidation and glucose oxidation pathways such as oleic acid, stearic acid, palmitic acid, linoleic acid, galactose, pyruvic and lactic acids are predominantly up regulated in patients with coronary artery disease and severity of diastolic dysfunction appears to be linked to increase in fatty acid oxidation and inflammation." | 3.91 | Untargeted metabolomic analysis of coronary artery disease patients with diastolic dysfunction show disturbed oxidative pathway. ( Basir, N; Bokhari, SS; Fatima, T; Hashmi, S; Iqbal, A; Musharraf, SG; Sami, SA; Sharif, H; Siddiqui, AJ, 2019) |
| "Trimetazidine, known as a metabolic modulator, is an anti-anginal drug used for treatment of stable coronary artery disease (CAD)." | 3.83 | Trimetazidine does not alter metabolic substrate oxidation in cardiac mitochondria of target patient population. ( Bakovic, D; Bulat, C; Cavar, M; Dujic, Z; Fabijanic, D; Karanovic, N; Kraljevic, J; Lavie, CJ; Ljubkovic, M; Marinovic, J; Wisloff, U, 2016) |
| " Multivariate analysis showed that statin dosage was independently associated with MD (OR:1." | 1.36 | Mitochondrial dysfunction induced by statin contributes to endothelial dysfunction in patients with coronary artery disease. ( Chan, HT; Dai, YL; Fong, B; Lau, CP; Lee, SW; Li, SW; Luk, TH; Siu, CW; Tam, S; Tse, HF; Yiu, KH, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Watanabe, R | 1 |
| Shirai, T | 1 |
| Namkoong, H | 1 |
| Zhang, H | 1 |
| Berry, GJ | 1 |
| Wallis, BB | 1 |
| Schaefgen, B | 1 |
| Harrison, DG | 1 |
| Tremmel, JA | 1 |
| Giacomini, JC | 1 |
| Goronzy, JJ | 1 |
| Weyand, CM | 1 |
| Fatima, T | 1 |
| Hashmi, S | 1 |
| Iqbal, A | 1 |
| Siddiqui, AJ | 1 |
| Sami, SA | 1 |
| Basir, N | 1 |
| Bokhari, SS | 1 |
| Sharif, H | 1 |
| Musharraf, SG | 1 |
| Cavar, M | 1 |
| Ljubkovic, M | 1 |
| Bulat, C | 1 |
| Bakovic, D | 1 |
| Fabijanic, D | 1 |
| Kraljevic, J | 1 |
| Karanovic, N | 1 |
| Dujic, Z | 1 |
| Lavie, CJ | 1 |
| Wisloff, U | 1 |
| Marinovic, J | 1 |
| Dai, YL | 2 |
| Luk, TH | 2 |
| Siu, CW | 2 |
| Yiu, KH | 2 |
| Chan, HT | 1 |
| Lee, SW | 1 |
| Li, SW | 2 |
| Tam, S | 2 |
| Fong, B | 2 |
| Lau, CP | 1 |
| Tse, HF | 2 |
| Wong, WK | 1 |
1 trial available for pyruvic acid and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Association of lower habitual physical activity level with mitochondrial and endothelial dysfunction in patients with stable coronary artery disease.
Topics: Aged; Blood Glucose; Coronary Artery Disease; Endothelium, Vascular; Female; Humans; Lactic Acid; Li | 2012 |
4 other studies available for pyruvic acid and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity.
Topics: Aged; B7-H1 Antigen; Bone Morphogenetic Protein 4; Coronary Artery Disease; Female; Humans; Immunity | 2017 |
Untargeted metabolomic analysis of coronary artery disease patients with diastolic dysfunction show disturbed oxidative pathway.
Topics: Adult; Biomarkers; Case-Control Studies; Coronary Artery Disease; Discriminant Analysis; Fatty Acids | 2019 |
Trimetazidine does not alter metabolic substrate oxidation in cardiac mitochondria of target patient population.
Topics: Aged; Coronary Artery Disease; Female; Humans; Male; Mitochondria, Heart; Oxidation-Reduction; Palmi | 2016 |
Mitochondrial dysfunction induced by statin contributes to endothelial dysfunction in patients with coronary artery disease.
Topics: Aged; Biomarkers; Brachial Artery; Coronary Artery Disease; Dose-Response Relationship, Drug; Endoth | 2010 |